- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (NASDAQ: ARWR), a focused nanomedicine holding company, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 13th Annual BIO CEO & Investor Conference at 8:00 a.m. Eastern time on Monday, February 14, 2011 at the Waldorf-Astoria Hotel in New York City, New York. Dr. Anzalone will be discussing recent Company developments and its opportunities in nanomedicine.
The presentation will be webcast live and can be accessed by visiting the Company's website at www.arrowheadresearch.com. A replay of the presentation will be archived on the Arrowhead website for 90 days.
About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company.
For more information, please click here
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Nanometrics to Present at the 19th Annual Needham Growth Conference December 22nd, 2016